+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 6Years - 17Years
All Genders
ID04743141

Long-Term Safety and Tolerability of Rimegepant for Acute Migraine Treatment in Children and Adolescents Aged 6 to Under 18 Years

Led by Pfizer · Updated on 2026-10-27

600

Participants Needed

124

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.

CONDITIONS

Brief Title

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Research Team

P

Pfizer Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here